Trial Profile
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms ORBIT1
- Sponsors Shire; Takeda
- 12 Feb 2024 According to a Takeda media release, based on results from study 1(NCT02605837) and study 2(NCT01642212), the FDA has approved EOHILIA (budesonide oral suspension), for people 11 years and older with eosinophilic esophagitis (EoE).
- 01 Dec 2023 Results of pooled post hoc analysis (n=76 from studies NCT01642212 and NCT02605837) assessing efficacy and safety of budesonide oral suspension (BOS) in adolescents with eosinophilic esophagitis published in the Journal of Pediatric Gastroenterology and Nutrition
- 20 Sep 2023 According to a Takeda media release, company announced that USFDA that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for TAK-721 (budesonide oral suspension) which is being investigated for the short-term treatment of eosinophilic esophagitis and company expects a decision from the FDA during the first half of 2024.